ALSO IN THIS ISSUE:

Letter from the Chair ........................................ 2
Proficiency Testing (PT): Overview .................. 3
NEW Continuous Quality Program ................. 6
PT: Provider Responsibilities ......................... 7
PT: COLA Processes ........................................ 8
PT: Approved Providers .................................... 10
PT: Regulated Analytes ................................... 11
COLA’s Symposium .......................................... 13
Advertisements .............................................. 5, 9 & 10
FROM THE CHAIR

It seems so wrong to think about “testing” of any kind during vacation season; however, we should never take a vacation from producing high quality laboratory test results. Proficiency Testing (PT) is a means of helping to ensure that your laboratory continually produces the highest quality, most accurate results possible.

In this issue of Insights, we hope to teach you about the PT process from several different perspectives: laboratory, PT provider, and COLA. This issue also includes lists of CMS-approved PT providers and CMS regulated analytes.

To further help you continually produce high quality laboratory test results, COLA is very excited to offer a new, innovative program: the Continuous Quality Program (CQP). Through the CQP's combination of education and consultation, we will help you educate and train your staff to look at testing from a “quality” perspective. The goal is to create an atmosphere where quality characteristics are so routine, they become second nature. More information can be found in the article on page 6.

Education is also at the forefront of our Symposium for Clinical Laboratories, which is detailed in a “pull-out” section at the end of this issue. In addition to high quality educational sessions, the Symposium for Clinical Laboratories is a great source for networking, comparing the latest laboratory instruments, test kits, and supplies; and for having fun! Won’t you join us in Baltimore in October?

W James Stackhouse, MD, MACP
Chair, COLA Board of Directors
Proficiency Testing: Overview

Proficiency Testing is similar to “unknowns” from high school chemistry lab.

Proficiency Testing, more commonly known as PT, is an external check used to monitor the quality of test results produced by the laboratory. It is a measure of the lab’s ability to analyze specimens of unknown values to obtain accurate results.

For regulated analytes (those analytes specifically listed in the CLIA regulations), the laboratory must be continuously enrolled in a PT program from the time patient testing is first performed. Failure to successfully participate in a PT program can lead to serious sanctions, such as an order to cease testing, loss of CLIA certification, and/or loss of Medicare & Medicaid reimbursements. (See p. 11 for a current list of regulated analytes.)

The Proficiency Testing process begins by choosing a PT provider from the list of CMS-approved providers. (See p. 10 for a current list of approved providers.) Depending on the analyte, the PT provider will deliver 2 – 5 specimens, known as challenges, 2 or 3 times per year. Providers will send five challenges for the regulated analytes at approximately equal intervals three times per year. Nonregulated analytes (those not listed in the CLIA regulations) are required to be challenged twice per year, either by PT or some other scientifically defensible means of comparison, such as split-sample analysis.

Laboratory Responsibilities

The most important aspect of PT is that the PT challenge specimens must be handled in the same manner as patient specimens. The primary purpose of PT is defeated if the challenges receive special treatment.

• The PT specimens should be incorporated into the routine patient workload.

• All testing personnel should perform PT at some point during the year. Do not delegate PT to only select personnel.

• PT challenges should not be repeated to report an average result. If patient specimens are not repeated, PT specimens should not be repeated.

• For each testing event, the Laboratory Director and the testing personnel (who actually performed testing for the PT event) sign a statement attesting that the PT challenges were handled in the same manner as patient specimens.

After testing is completed, submit results to the PT provider within the required time frame. The laboratory receives a grade of zero for the entire testing event if results are not submitted or if they are submitted after the cut-off date.

Other important PT rules include:

• Do NOT discuss PT or PT results with any other laboratory (including satellite, affiliate, and reference laboratories) prior to the result submission date.

• Do NOT send PT specimens to another lab for testing. This also includes satellite, affiliate, and reference laboratories. If patient specimens would normally be referred for further testing, indicate this on the PT result form, but do NOT send the specimen.

• Do NOT perform testing on PT specimens received from another lab, but notify CMS that they were received.

Overview

Choose a PT provider from CMS-approved list

PT provider periodically sends unknown specimens

Handle PT specimens in the same manner as patient specimens

Report results to PT provider

PT provider checks results, compares them to results from similar laboratories, and prepares and sends graded report packets to labs

>> CONTINUED ON PAGE 4
Continued from page 3

**Proficiency Testing: Overview**

- Document everything involved in performing Proficiency Testing and keep this documentation for at least two years.

It is good laboratory practice to maintain the PT specimens under proper storage conditions until the graded report packet is received from the PT provider. This means that the specimens will be available for repeat testing if the PT performance review deems it necessary.

**Review PT Performance**

Laboratories should promptly review and evaluate the data in the graded report packet when it is received.

First, review the report for clerical, transcription, and/or omission errors.
- Ensure that the CLIA ID number is correct.
- Confirm that there is a score for all tests for which results were submitted.
- Verify that the PT provider used the actual submitted results when grading the event.
- Check to see that the correct test method codes were used, to ensure that results were compared to the correct peer group.

Next, review and evaluate the individual challenges.
- Use the Standard Deviation (SD) and Standard Deviation Index (SDI) to help determine if the test system is showing instability or imprecision.
- Pay attention to challenges where consensus is not obtained (automatic scores of 100%). “Self-grade” by comparing submitted results to the provider’s expected results as well as results obtained by other laboratories.
- Compare current results to past results to detect trends and/or method bias.

If all results are acceptable, document the review, and maintain all documentation for the required time period which, in most cases, is a minimum of two years. The retention period is determined by Federal, State, local, and institutional requirements. Ensure that you meet the longest retention times.

If any results are unacceptable, determine the cause, implement and evaluate corrective actions, and document everything and maintain documentation for the required time period.

**Evaluate PT Performance**

Looking at the scope of the problem can help determine its root cause. A problem with the PT specimen itself is indicated if more than one analyte from the same specimen is involved. Improper handling (such as improper reconstitution, or pipetting or dilution errors) and evaporation of the aliquot used for testing are possible causes.

Instrument or test system problems are indicated if more than one analyte or specimen on the same instrument or test system is involved, or if only analytes in a certain range are affected (which indicates a linearity or calibration issue). If the test system or instrument is the cause, patient results should also be evaluated.

If more than one instrument or test system is affected, look for factors that are common to all systems involved. The most obvious commonality is testing personnel. Confirm that all personnel are still competent to perform testing, and provide retraining and/or continuing education when necessary. Don’t overlook other common factors, such as unforeseen effects of new policies, modified kit, reagent, or specimen storage facilities, and/or unusual environmental factors (power outage, extreme temperature changes, electronic interference, etc.). Patient results should also be evaluated in this circumstance.

Finally, look at the overall grade for the PT event. Each testing event has three possible outcomes: satisfactory performance, unsatisfactory performance, or unsuccessful performance.

- **Satisfactory performance** is attaining the minimum score for an analyte, test, subspecialty, or specialty for a single testing event. For most specialties, the minimum score is 80%; however, exceptions do exist. For example, in Immunohematology, a score of 100% is required when performing ABO & Rh typing and/or compatibility testing.
- **Unsatisfactory performance** is defined as failure to attain the minimum score for an analyte, test, subspecialty, or specialty for a single testing event.
- **Repeated unsatisfactory performance** becomes **unsuccessful performance**, which is failure to attain a satisfactory score for an analyte, test, subspecialty, or specialty for two consecutive or two-out-of-three consecutive testing events. unsuccessful performance can lead to CMS sanctions including an order to cease testing or limitation, suspension, or revocation of CLIA certification.

>> continued on page 5
To resolve unsuccessful performance, laboratories must:

• Investigate the root cause of the unsuccessful performance.
• Implement and evaluate corrective actions.
• Notify accrediting agencies or CMS of actions taken.

Laboratories that have been required to cease testing due to poor PT performance will also have to successfully complete two consecutive PT events, which can be either scheduled or off-cycle events, before patient testing can be reinstated.

All actions taken during the Proficiency Testing process have to be documented. This includes all records – from initial receipt in the laboratory, through PT specimen processing and handling, actual test performance, and result submission, to reviewing and evaluating graded reports, investigating problem root causes, and implementing and evaluating corrective actions.

All correspondence with PT providers, including details of any phone calls, should also be maintained. All documentation must be readily available for at least two years. (As stated above, the retention period may be longer in some areas.)

Quality patient care is a goal of all clinical laboratories. Producing accurate, reliable laboratory test results helps ensure quality patient care. PT is a means to monitor the quality of laboratory test results. Therefore, consistent, successful performance of Proficiency Testing is a goal every laboratory should strive to attain.

NOTE:

1 This is not an all-inclusive list. For more information, refer to subpart H of the CLIA regulations. http://www.cdc.gov/clia/regs/subpart_h.aspx

CONTINUED FROM PAGE 4

PROFICIENCY TESTING: OVERVIEW

BUYING ALL TYPES OF USED LABORATORY EQUIPMENT

Used laboratory and medical equipment only has a fixed life until it has been replaced by newer or less expensive technology. Sell your equipment to us now while it still has value.

“In an industry where recouping every dollar is necessary to survive the decrease in reimbursement for lab services over time, recycling used equipment is a good source of potential revenue for both labs and medical practices. I strongly recommend you contact Medical Equipment Recycling, INC. You can rely on them for sound advice and good pricing when recycling equipment.”

Libby Koollmeyer - Laboratory Management Resources

Abbott Architect i1000, i2000, C8000, CI8200, C16000
Abbott Cell Counters – CD 3200CS, 3200SL, 3700CS, 3700SL, Emerald, Ruby, Sapphire
ABX Micros 45, Micros 60, Micros 80im
ABX Pentra 60, Pentra 60C+, Pentra 120DR, Pentra 400
ACL 1000 & 10,000 Coag.
Alfa Wassermann Alera Chemistry
Bayer Advia 120 & 2120
Beckman Access II, DXC 600 Pro, DXC600i, DXC600 Pro, Dxi 800
Clinical Data ATAC 8000 Chemistry System
DPC Immulite Plain & 1000 models
Ortho Clinical DT60 II (3 modules) Vitros 250, Vitros 350
Roche Integra 400 Plus, Mira Plus, Mira Plus CC, Mira S
Sysmex K-1000, KX-21N, XE-2100, XS-1000i, XT-2000i
Tosoh AIA 360, AIA 800i, G7, G8
Vital Diagnostics Envoy 500
MANY MORE! CALL US!

540-776-3635 • medicalequipment@verizon.net • www.medicalearnposurecycling.com
Continuous Quality Program

COLA is a physician-directed organization whose purpose is to promote excellence in laboratory medicine and patient care through a program of voluntary education, consultation, and accreditation.

Since “excellence in laboratory medicine and patient care” translates to quality patient care, quality has always been the heart of COLA’s mission. Through the COLA accreditation program, your laboratory’s quality has been evaluated through biennial surveys, which provide a snapshot of how your laboratory complies with federal and state regulations at the time of the survey. However, COLA knows that you want to provide excellent laboratory medicine and patient care at all times; that you want to create a culture of quality within your laboratory; and that you want to integrate quality policies and procedures into your daily routine. COLA’s new **Continuous Quality Program** can help you do this.

Through the launch of several new initiatives, COLA can help you grow beyond mere compliance and develop a culture of quality that permeates your laboratory on a daily basis. Through COLA’s **Continuous Quality Program** and our robust offerings of online courses, educational products, symposia, and live webinars, we can help you obtain the following positive outcomes:

- Heightened laboratory performance resulting in more accurate results;
- More reliable test results resulting in greater convenience for patients;
- More reliable test results resulting in greater efficiencies for providers;
- Laboratorians who avoid the disruptions and increased costs which occur with citations;
- Increased savings and greater efficiencies, since accurate testing decreases redundant expenditures associated with flawed test results.

Our Continuous Quality Advisors will work with your laboratory to help you obtain these outcomes and demonstrate a commitment to quality. One way they do this is by helping your laboratory personnel become familiar with and utilize the practical, informative, and educational resources available on www.COLAcentral.com and www.LabUniversity.org.

A recent statistical analysis of over 3000 COLA surveys conducted in 2011 showed that two of the top ten citations involved Proficiency Testing (PT) issues. PT issues could be due to problems in your test systems that can affect the quality of your laboratory results and consequently diminish the quality of your patient care.

**Proficiency Testing issues could be due to problems in your test systems that can affect the quality of your laboratory results and consequently diminish the quality of your patient care.**

Other common citations were found in the areas of Quality Control, personnel training and competency, and instrument calibration and maintenance. A problem in any one of these areas could lead to questions about the accuracy of laboratory test results. This lack of confidence leads to an increase in repeat testing, which utilizes additional reagents and supplies and wastes time that could be spent on other tasks. The **Continuous Quality Program** incorporates targeted educational resources to address specific issues such as these, and to facilitate improving and maintaining quality throughout your laboratory.

With the right policies and procedures in place, and properly trained and competent staff to carry them out, you can have an efficient laboratory that produces high quality, accurate test results leading to excellence in patient care. We here at COLA want to work with you through our **Continuous Quality Program** to ensure that this happens consistently in your laboratory.
Proficiency Testing: Provider Responsibilities

CLIA requirements also apply to PT providers.

Once approved by the Centers for Medicare and Medicaid Services (CMS), Proficiency Testing (PT) providers are obligated to perform specific responsibilities, which include:

- providing technical assistance to laboratories;
- providing quality PT challenge specimens that mimic patient specimens during testing;
- scientifically determining correct/expected results for each challenge;
- notifying labs of shipping schedules;
- evaluating and scoring testing results;
- providing event and summary reports; and
- resolving technical, administrative, and scientific problems.

When providers receive lab-submitted results, the results are compared to results submitted by other laboratories, checked to determine if correct/expected results are obtained, and graded so the laboratory can determine whether satisfactory or unsatisfactory performance was achieved. PT providers will also calculate statistical data (i.e., mean, standard deviation, standard deviation index, and coefficient of variance) and include them in the report packet for the laboratory to use in evaluating PT performance.

The group used for comparison depends on the specific analyte, the test methodology, and the number of labs testing the analyte.

- The peer group is the most ideal since it consists of all laboratories using the same method and instrument to test for the specific analyte. Since there must be a minimum number of labs for the group to be statistically valid, it is not always possible to be compared to a peer group.
- If that minimum number is not met, the PT provider will use a method group to compare results. The method group consists of labs using the same method (i.e., photometry, impedance, ELISA, etc.) but not necessarily the same instrument.
- If there are not enough laboratories using the same method to constitute a statistically valid group, the next group used for comparison is the all methods group, which, as the name implies, contains all methods of testing for the specific analyte.

PT providers are required to share information on laboratory performance with accrediting agencies and CMS, so laboratory PT performance can be monitored by these agencies. Accredited laboratories must tell their PT providers which accrediting organization (AO) will monitor the PT results and give permission for the PT provider to share their results with their AO.

NOTE:

1 List is NOT all inclusive – for a complete listing of PT provider responsibilities, refer to Clinical Laboratory Improvement Amendments, subpart I, section 493.901; last accessed July 2012; http://wwwn.cdc.gov/clia/regs/subpart_i.aspx#493.901
Proficiency Testing: COLA Processes

COLA works hand-in-hand with Proficiency Testing providers to monitor laboratory PT performance and then works hand-in-hand with laboratory personnel to resolve PT problems and improve laboratory quality.

As required by the Centers for Medicare and Medicaid Services (CMS), COLA monitors laboratory Proficiency Testing (PT) performance of regulated analytes. The monitoring process begins in the Fall when COLA contacts each Proficiency Testing (PT) provider to obtain a list of their offerings and their shipping calendar for the upcoming year. COLA uses this information to develop a schedule that defines the time periods when results from the three required events for the year should be available from each provider. The schedule is used throughout the year to monitor the data submitted by the PT providers.

When the PT data is obtained, it is analyzed to determine each laboratory’s PT performance. This analysis results in two possible scenarios:

• No PT performance problems are identified.
  The laboratory has obtained passing scores for each analyte, test, subspecialty, or specialty. No further action is required until the next PT event when the process is repeated.

• PT performance problems are identified.
  The laboratory has received at least one failing score. Previous PT event scores are checked to determine a pattern of performance, which determines the next actions to be taken.

COLA understands that laboratory personnel may need help when investigating the root cause of PT failures, developing corrective actions to address them, and/or developing plans to prevent them from occurring in the first place, so we offer several different resources as assistance. These resources include online courses & webinars, downloadable LabGuides and, our latest resource, the new Continuous Quality Program. (See p. 6 for more information on the Continuous Quality Program.)

Several classes at our next Symposium for Clinical Laboratories also focus on Proficiency Testing. For additional information, see the special Symposium section beginning on p. 13.

Documentation of corrective action taken must be sent to COLA for review when a pattern of unsuccessful performance is seen. The original documentation must be retained in the laboratory for the appropriate retention period and must be available for review by the COLA surveyor. Copies of the documentation can be mailed, faxed, or emailed to COLA, or uploaded to the document repository on www.COLAcentral.com so it can be reviewed to resolve the unsuccessful performance event.

The following patterns indicate unsuccessful performance:

• FF (last two events)
• FPF (last three events)
where “F” is a failing score and “P” is a passing score.

The laboratory must cease testing the analyte, test, subspecialty, or specialty when a pattern of repeated unsuccessful performance occurs:

• FFF (last three events)
• FFPF (last four events)
• FPFF (last four events)
• FPFPF (last five events)

>> CONTINUED ON PAGE 9
To reinstate testing, the laboratory must pass two consecutive PT events. These events can be two routine events, two off-schedule events, or one routine and one off-schedule event. The PT provider will send results to COLA automatically, but this may not happen until several weeks after the laboratory receives a copy of the graded results. To allow the laboratory to reinstate testing as soon as possible, COLA encourages the laboratory to send us a copy of their results, after they have been reviewed and evaluated.

The goal of Proficiency Testing is help ensure accurate laboratory testing which, in turn, leads to quality patient care. COLA helps achieve this goal by monitoring PT performance and working with COLA laboratories to address PT failures.

NOTES:
1. Proficiency Testing (and/or other means used to verify test accuracy) for unregulated analytes is monitored through the PT review process during each laboratory’s biennial survey.
2. In most cases, documentation must be retained for at least two years. The required retention period is the longest period mandated by Federal, State, local, and/or institutional regulations.
3. Unless the laboratory’s first PT event is a failing score, the patterns listed in this article always follow two consecutive passing events.
Calibration verification/linearity testing has a new address.

Yes, it’s that easy.
1: Open. 2: Dispense. 3: Run.

Calibration verification/linearity testing doesn’t get much easier than VALIDATE®. Our liquid, ready-to-use testing kits minimize the need for manual dilutions, saving you time and making your job easier. Plus, you get our promise of 100% satisfaction, backed by experts who are ready to help you with any questions or concerns.

To learn more about VALIDATE®, call us at 1-800-377-9684 or visit www.mainestandards.com/POL.htm.

CMS Approved Proficiency Testing Providers

ACCUTEST, INC.
PO. Box 999
Westford, Massachusetts 01886-0031
(800) 665-2575

AAFP-PT
11400 Tomahawk Creek Parkway
Leawood, Kansas 66211-2672
(800) 274-7911

AMERICAN ASSOCIATION OF BIOANALYSTS (AAB)
205 West Levee Street
Brownsville, Texas 78520-5596
(800) 234-5315

AMERICAN PROFICIENCY INSTITUTE (API)
1159 Business Park Drive
Traverse City, Michigan 49686-8670
(800) 333-0958

CALIFORNIA THORACIC SOCIETY (CTS)
575 Market Street, Suite 2125
San Francisco, California 94105-2870
(415) 536-0287

THE COLLEGE OF AMERICAN PATHOLOGISTS (CAP) - SURVEYS
College of American Pathologists
325 Waukegan Road
Northfield, Illinois 60093-2750
(847) 832-7000

EXTERNAL COMPARATIVE EVALUATION FOR LABORATORIES - EXCEL
College of American Pathologists
325 Waukegan Road
Northfield, Illinois 60093-2750
(800) 323-4040

MEDICAL LABORATORY EVALUATION (MLE) PROGRAM
25 Massachusetts Avenue, NW
Suite 700
Washington, DC 20001-7401
(800) 338-2746 or (202) 261-4500

COMMONWEALTH OF PENNSYLVANIA
Department of Health
Bureau of Laboratories
P. O. Box 500
Exton, Pennsylvania 19341-0500
(610) 280-3464

PUERTO RICO PROFICIENCY TESTING SERVICE
Public Health Laboratories of Puerto Rico
P. O. Box 70184
San Juan, Puerto Rico 00936-8184
(787) 724-6827

WSSLH PROFICIENCY TESTING PROGRAM
465 Henry Mall
Madison, Wisconsin 53706-1578
(800) 462-5261

RESOURCE:
Regulated Analytes for Nonwaived Testing

**MICROBIOLOGY**

**Bacteriology**
- Aerobic/Aerobic Culture & Identification
- Antibiotic Susceptibility Testing
- Direct Bacterial Antigen Detection
- Gram Stain

**Mycobacteriology**
- Acid Fast Stain
- Mycobacteriology Identification
- Mycobacteriology Susceptibility Testing

**Mycology**
- Culture and Identification

**Parasitology**
- Presence or Absence of Parasites
- Identification of Parasites

**Virology**
- Direct Viral Antigen Detection
- Viral Isolation and Identification

**CHEMISTRY**

**Routine Chemistry**
- Alanine Aminotransferase (ALT or SGPT)
- Albumin
- Alkaline Phosphatase
- Amylase Aspartate Aminotransferase (AST or SGOT)
- Bilirubin, total
- Blood Gases:
  - pH
  - pCO2
  - pO2
- Calcium, total
- Chloride
- Cholesterol, total
- Cholesterol, HDL
- Creatine Kinase, total
- Creatine Kinase, Isoenzyme (CK-MB)
- Creatinine
- Glucose
- Iron, total
- Lactate Dehydrogenase (LDH), total
- LDH Isoenzymes (LDH1/LDH2)
- Magnesium
- Potassium
- Sodium
- Total Protein
- Triglycerides
- Urea Nitrogen
- Uric Acid

**Toxicology**
- Blood Alcohol
- Blood Lead
- Carbamazepine
- Digoxin
- Ethosuximide
- Gentamicin
- Lithium
- Phenobarbital
- Phenyltoin
- Primidone
- Procainamide and Metabolite
- Quinidine
- Theophylline
- Tobramycin
- Valproic acid

**HEMATOLOGY**

**Cell Identification**
**WBC Differential**
**Erythrocyte Count**
**Hematocrit**
**Hemoglobin**
**Leukocyte Count**
**Platelet Count**
**Fibrinogen**
**Partial Thromboplastin Time**
**Prothrombin Time**

**IMMUNOHEMATOLOGY**

**ABO Group**
**D (Rho) Typing**
**Unexpected Antibody Detection**
**Compatibility Testing**
**Antibody Identification**

**RESOURCES:**
Centers for Medicare and Medicaid Services, CLIA Brochure #8, last accessed July 2012
COLA’S SYMPOSIUM FOR CLINICAL LABORATORIES

Growing strong for you.

October 10-13, 2012
Hilton Baltimore

Jointly sponsored by the University of Wisconsin School of Medicine and Public Health and COLA.
Schedule at-a-Glance

Note: topics and schedule may change. Lab Director Qualification Sessions that offer CME credit through the University of Wisconsin School of Medicine and Public Health are indicated with 11.

Wednesday, October 10, 2012
10:00a – 8:30p Participant Check-in

Thursday, October 11, 2012
7:00a – 8:00a Breakfast in Exhibit Ballroom
7:00a – 8:00a Basics of Laboratory Medicine for Physicians
Verlin Janzen, MD, FAFPP
8:00a – 10:00a AM General Session 11
8:00a – 8:30a Opening Remarks and Overview
John T. Daly, MD
8:30a – 9:00a Current Concerns & Potential Improvements
John T. Daly, MD
9:00a – 10:00a CLIA Hot Topics: Personnel Competency and IQCP
Judy Yost, MA, MT(ASCP)
10:00a – 10:30a Exhibits and Break in Exhibit Ballroom
10:30a – 12:00p Breakout Session A (select one)
A01 Effective Training
Barry Craig, MLT
A02 Introduction to Proficiency Testing
Verlin Janzen, MD, FAFPP & John T. Daly, MD
A03 Manuals & Records for Labs Without an LIS
Elizabeth Staubs, MT(ASCP/SH)
A04 Getting the Most Out of Your Proficiency Testing
Rick Gates, MLT(ASCP) & Leon Headley, MLS, CT(ASCP)
A05 Phlebotomy CSI (Challenging Sticks Investigation)
Lisa O. Baliance, BSMT(ASCP), CLC(AMT)
A06 The Right Stuff: Getting the Right Equipment for Your Lab
Tim Dumas, CLS
12:00p – 1:00p Lunch
1:00p – 2:00p Breakout Session B (select one)
B11 Technology Workshop: Chemistry Instruments
B12 Personnel & Procedures for CLIA Compliance
Ann Bachman, CLC(AMT), MT(ASCP)
B13 Becoming a Quality Control Expert
Terri Wolek, MT(ASCP)
B14 Complying With the CLIA Personnel Criteria
Pam Gottspinner, MT(ASCP) & Irwin Rothenberg, MBA, MS, MT(ASCP)
B15 Best Practices for Waived Testing
Elizabeth Staubs, MT(ASCP/SH) & Barry Craig, MLT
B16 Pre-analytical Benchmarks and Process Improvement
Lisa O. Baliance, BSMT(ASCP), CLC(AMT) & Dennis Ernst, MT(ASCP)
B17 How Can CLSI Documents Benefit Your Lab?
Luann Ochs, MS
3:30p – 4:00p Exhibits and Coffee Break in Exhibit Ballroom
4:00p – 5:30p Breakout Session C (select one)
C21 The Impact on Laboratories by the Ever-changing Arena of Healthcare – HowHITECH EMR/EHR Stimulus, ICD-10, LOINC, ACOs, Molecular Testing and Integrated Diagnostics May Affect Your Lab
Curt Johnson
C22 QA of PT: Proficiency Testing Problem Resolution
Verlin Janzen, MD, FAFPP & John T. Daly, MD
C23 Calibration Verification & Performance Specifications
Judy Dixon, MS, BSMT(ASCP)
C24 Incident Management
Irwin Rothenberg, MBA, MS, MT(ASCP) & Leigh Ann Smith, MLS(ASCP)
C25 Venipunctures: Managing the Risk
Dennis Ernst, MT(ASCP)
C26 I'm a Lab Consultant, Now What? 10 Business Basics to Get You Started
Barry Craig, MLT
6:00p – 8:00p Reception for participants, faculty, and exhibitors

Friday, October 12, 2012
7:00a – 8:00a Breakfast in Exhibit Ballroom
8:00a – 9:30a AM General Session
8:15a – 9:30a HIV Diagnosis and Treatment: The Importance of Laboratory Medicine
Donna Sweet, MD, MACP
9:30a – 10:30a Exhibits and Break in Exhibit Ballroom
10:30a – 12:00p Breakout Session D (select one)
D31 Technology Workshop: Laboratory Information Systems
Verlin Janzen, MD, FAFPP & John T. Daly, MD
D32 Introduction to Quality Control
D33 HIPAA, Ethics & Confidentiality
Tim Dumas, CLS & Barry Craig, MLT
D34 Complying with the COLA QC Criteria
D35 OSHA Training: Bloodborne Pathogens
Elizabeth Staubs, MT(ASCP/SH)
D36 Billing & Coding Basics
Shannon O. DeConda, CPC, CPC-I, CPMA, CMSCS, CEMC, CRITT
D37 Let’s Talk About QC Practices!
Terri Wolek, MT(ASCP)
12:00p – 1:00p Lunch
1:00p – 2:30p Breakout Session E (select one)
E41 Post-analytical Top 10
Dennis Ernst, MT(ASCP)
E42 Popular Tests: Fad, Fallacy or For Real?
Verlin Janzen, MD, FAFPP
E43 Are You Ready for a Billing/Coding Audit?
Joanne Broccolino, BS, MT(ASCP)
E44 COLA Users Group: Accreditation Update
Irwin Rothenberg, MBA, MS, MT(ASCP) and Rachael Kelly
E45 LEAN Six Sigma for the Lab
Joanne Broccolino, BS, MT(ASCP)
E46 Are You Ready for a Billing/Coding Audit?
Shannon DeConda, CPC, CPC-I, CPMA, CMSCS, CEMC, CRITT
2:30p – 3:30p Ice Cream Social and Exhibits in the Exhibit Ballroom
3:30p – 5:30p PM General Session
3:30p – 4:30p Right Diagnosis, Right Lab Test, Right on Time
Michael Laposata, MD, PhD & James Meisel, MD, FACP
4:30p – 5:30p Jumping the Generation Gap
Tim Dumas, CLS
4:30p – 6:00p Concurrent LD session: Preparing for inspection
Ann Bachman, CLC(AMT), MT(ASCP)
5:30p or 6:00p Adjourn

Saturday, October 13, 2012
7:00a – 7:15a Breakfast in General Session Ballroom
7:00a – 1:30p AM & PM General Session
7:15a – 8:15a Lab Director Responsibilities: Regulatory
Verlin Janzen, MD, FAFPP
8:15a – 9:15a COLA Users Group: Accreditation Update
Irwin Rothenberg, MS, MBA, MT(ASCP)
9:30a – 10:45a Perspectives on Being a Laboratory Director – Financial Considerations
Tim Dumas, CLS
10:45a – 11:45a Negotiating with Insurance Companies
Tim Dumas, CLS
11:45a – 12:00p Lunch
12:00p – 1:00p Lab Director Responsibilities: Practical Application
Verlin Janzen, MD, FAFPP
1:00p – 1:30p Can We Speak Frankly About Being a Lab Director in 2012?
Verlin Janzen, MD, FAFPP
1:30p Conclusion and Adjourn – Travel Safely
COLA Symposium for Clinical Laboratories
Growing Strong for You!

COLA’s Symposium for Clinical Laboratories has not only maintained its prominent standing in the laboratory medicine field, it has continued to improve and grow stronger – even in the recent times of economic uncertainty.

That is due to the exceptional, rewarding, educational experience you are sure to have when you attend the Symposium. It does not matter if you are a first-time or repeat attendee, or a novice or seasoned laboratory professional, as shown by comments from past attendees.

“Thank You! This is my first COLA experience. I feel you’ve provided many tools for me to utilize in the future at my laboratory.”

“I have attended many conferences hosted by ASCP, AMT, ASCLS, CLMA, and COLA in the past 18 years. COLA Symposia by far are the most organized, efficiently executed, and useful. Even the attendees seem to be more engaged and cared about learning the material.”

Our Symposium staff work diligently to schedule timely, relevant, informational sessions presented by enthusiastic, dynamic speakers. While the Lab Director Program1 is the heart of the Symposium, laboratory personnel from phlebotomists to lab assistants to laboratory scientists to managers are sure to be intrigued by the compelling, interactive sessions presented by our knowledgeable, well-respected faculty, who are passionate about the field of laboratory medicine.

“I talked to several people about a hematology issue I was having and did not get a logical response. I ran this issue by her and she hit the root of the problem spot on! Thanks so much!”

– comment about Terese Wolek, MT(ASCP), faculty

“Very knowledgeable and able to communicate well with entry-level LDs” “Superb presenter”

– comments about Verlin Janzen, MD, faculty

Attending the COLA Symposium for Clinical Laboratories will also afford the opportunity to visit our outstanding Exhibit Hall, where leading manufacturers will be exhibiting the most up to date laboratory products! Our exhibitors understand your laboratory needs, relish your enthusiasm, and help you learn about the latest technologies so you can meet your needs and benefit your lab.

Our Symposium staff research every detail to make your stay with us an exceptional one. For this conference, they have selected the Hilton Baltimore, recipient of the 2012 TripAdvisor Certificate of Excellence Award, which is an honor awarded to establishments that achieve outstanding traveler reviews on TripAdvisor, the world’s largest travel site.

Won’t you grow stronger with us? Join us in Baltimore in October 2012 by registering for the COLA Symposium for Clinical Laboratories. (Click on the link for more Symposium information, including the full schedule and session descriptions.)

NOTE:

1 The Lab Director Program has been approved by the Centers for Medicare and Medicaid Services (CMS) as a means for physicians to obtain the required 20 CME credits in laboratory medicine to qualify as directors of laboratories performing moderate complexity testing. The LD Program is offered at the Symposium for Clinical Laboratories and as online courses offered through COLA’s LabUniversity at www.LabUniversity.org.
Speakers of Note

To provide you with the best possible learning experience, COLA strives to provide outstanding, enthusiastic Symposium speakers who are well-known and well-respected in the field of laboratory medicine. We’d like to take a few moments to introduce a few of these dynamic individuals.

JAMES MEISEL, MD, FACP

Dr. Meisel has an extensive background in many different aspects of medicine and laboratory medicine.

- Education: Dr. Meisel is an Associate Professor of Medicine at Boston University School of Medicine in Boston, MA. He serves as a general internal medicine doctor practicing at Boston University Medical Center, where he works as both an academic hospitalist and a clerkship director for students on their internal medicine rotations. Before joining the BU faculty in 2008, he served as an inpatient clinician educator, resident clinic preceptor, and primary care physician at Massachusetts General Hospital in Boston.

- Faculty Development: Over the last decade, Dr. Meisel participated in faculty development programs at the Harvard Schools of Medicine, Business and Graduate Education, National Library of Medicine Medical Informatics, McMaster University How to Teach Evidence Based Clinical Practice, and the University of Massachusetts Medical School Teachers of Tomorrow program.

- Government Relations: While at Massachusetts General, Dr. Meisel served on the Clinical Laboratory Advisory Committee, and since 2008, has been an active member of the Clinical Laboratory Integration into Healthcare Collaborative (CLIHC®) workgroup at the CDC.

Dr. Meisel received his bachelor’s degree in Economics at Brandeis University prior to earning his doctorate at the State University of New York at Buffalo School of Biomedical Sciences. He completed his internship and residency in internal medicine at New England Deaconess Hospital and Harvard Medical School, both in Boston.

MICHAEL LAPOSATA, MD, PHD

Dr. Laposata also has noted expertise in many varied aspects of medicine and laboratory medicine.

- Research: His research program, with more than 150 peer reviewed publications, has focused on fatty acids and their metabolites. His research group is focused on the study of fatty acid alterations in cystic fibrosis.

- Clinical: Dr. Laposata’s clinical expertise is in the field of blood coagulation, with a special emphasis in the diagnosis of hypercoagulable states.

- Extraordinary Clinical Achievement: Dr. Laposata implemented a system whereby the clinical laboratory data in coagulation and other areas of laboratory medicine are systematically interpreted, resulting in the generation of a patient-specific, narrative paragraph by a physician with expertise in the area. This service is essentially identical to the service provided by physicians in radiology and anatomic pathology, except that it incorporates clinical laboratory test results. In 2005, Dr. Laposata was recognized for this innovation by the CDC’s Institute of Quality in Laboratory Medicine.

- Education Awards: Dr. Laposata is the recipient of 14 major teaching prizes from Harvard, the Massachusetts General Hospital, and the University of Pennsylvania School of Medicine.

Among others, these awards include:

- The 1989 Lindback award (a teaching prize with competition across the entire University of Pennsylvania system);
- The 1998 A. Clifford Barger mentorship award from Harvard Medical School;

>> CONTINUED ON PAGE 16
• Election to the Harvard Academy of Scholars in 2002 and to the Vanderbilt University School of Medicine Academy for Excellence in Teaching in 2009, and
• What he considers his highest award – achieved by vote of the graduating class – for teaching in years 1 and 2 at Harvard Medical School in 1999, 2000, and 2005.

Dr. Laposata is the Edward and Nancy Fody Professor of Pathology and Medicine at Vanderbilt University School of Medicine. He is also the pathologist-in-chief at Vanderbilt University Hospital and the director of clinical laboratories. He received his MD and PhD from Johns Hopkins University School of Medicine and completed a postdoctoral research fellowship and residency in Laboratory Medicine (Clinical Pathology) at Washington University School of Medicine in St. Louis. His first faculty position was at the University of Pennsylvania School of Medicine in Philadelphia in 1985, where he was an Assistant Professor and director of the hospital's coagulation laboratory. In 1989, he became Director of Clinical Laboratories at the Massachusetts General Hospital and was appointed to the faculty in pathology at Harvard Medical School.

On Friday afternoon, October 12, Drs. Laposata and Meisel join forces to present:

Right Diagnosis, Right Laboratory Tests: Exploring the Challenges and Role of the Medical Technologist in 2012

This presentation will explain the challenges of appropriate test selection and correct results interpretation that all practicing clinicians face. The presenters will use an innovative “dueling doctors” format, featuring a laboratory director (Dr. Laposata) and an internist (Dr. Meisel), discussing the sometimes mutually exclusive challenges in achieving accurate and rapid diagnosis.

At the end of this session, attendees will be able to:
• Describe the sometimes mutually exclusive challenges faced by the laboratory director and the general internist in test selection and results interpretation;
• Explain how highly trained testing personnel may provide accurate test identification guidance to the clinician;
• Describe the potential benefits and challenges that each of the case studies presents in your clinical setting.

“The dueling docs were articulate, engaging, funny and knowledgeable. The audience was thrilled to have their role as CLSs/MLSs in medicine so well understood and appreciated. Dr. Meisel brought up problems he was having diagnosing patients and which lab test would be best in certain situations and Dr. Laposata explained the complexity of laboratory testing. Both men looked to the MLS and the DCLS (in the future) to answer their questions about testing.”

Comments about Michael Laposata, MD, PhD and James L. Meisel, MD, FACP


DONNA SWEET, MD, MACP

Dr. Sweet is best known for her medical treatment and research on AIDS. She has been recognized locally, nationally, and internationally for her work, which includes:
• Extensive work with the Health Resource Service Administration on Ryan White issues;
• Past national Co-Chair of the CDC HRSA AIDS Advisory Council (CHAC);
• Certified HIV specialist by the American Academy of HIV Medicine, of which she is the current Board Chair;
• Principal Investigator and Director of the Kansas AIDS Education and Training Center.

Additional Ryan White accomplishments of note include:
• She has administered Ryan White Part B funds at her clinic since these funds first became available for patients;
• Principal Investigator and Medical Director of the Ryan White Part C Early Intervention Program since 1993;
• Granted funds to begin a Ryan White Part D Family Services program to care for women, infants, children and youth who are infected and affected by HIV in 2009.

>> CONTINUED ON PAGE 17
In March 2000, the AMA identified Dr. Sweet as one of four “Heroes in Medicine” by awarding her with one of the first *Pride in the Profession* awards, for her leadership in confronting AIDS issues and her care for patients with the disease.

She lectures in her home state of Kansas as well as nationally and internationally to educate other health care providers about HIV and AIDS. She works closely with the Eurasian Medical Education Program of the American College of Physicians and has been educating physicians about HIV/AIDS internationally for more than 11 years.

In addition to her work with HIV/AIDS, Dr. Sweet is actively involved with the American College of Physicians and COLA and the American Medical Association. She is

- Past Chair of the American College of Physicians Foundation Board;
- Chair Emeritus of the American College of Physicians Board of Regents, where she served as Chair for the 2005-2006 term. At the conclusion of her term, she was named a Master of the ACP (MACP) for her service to medicine and to the American College of Physicians.
- A past ACP representative to the COLA Board of Directors;
- Member and past Chair of the COLA Board of Directors;
- ACP delegate to the AMA; and
- A member of the Council on Medical Service of the AMA.

Dr. Sweet began her medical career when she graduated from the University of Kansas School of Medicine and completed her residency training at the University of Kansas-Wichita and affiliated hospitals. She is board-certified in internal medicine and is a Professor of Internal Medicine at the University of Kansas School of Medicine-Wichita. She is also the Director of Internal Medicine Education at Via Christi Regional Medical Center-St. Francis in Wichita.

On Friday morning, October 12, Dr. Sweet will be presenting: **HIV Care: What’s New in Laboratory Medicine**

HIV testing and care is rapidly changing. During this session, Dr. Sweet will provide the most recent updates on HIV infection and the importance of early HIV testing. She will discuss acute HIV infection and the new developments in HIV immunoassays as well as the recent FDA approval of in-home HIV testing.

At the end of the session, attendees will be able to:

- Summarize the rationale behind the importance for early HIV testing,
- Utilize available methods to identify acute HIV infection,
- Outline and evaluate the upcoming new testing algorithm for HIV infection,
- Examine the importance of laboratory medicine in the care of HIV patients.

“I found this to be a very valuable presentation, serving to enlighten us on the current HIV situation (in this country and the world). Dr. Sweet presented personal and down to earth examples of community impact as well as an excellent description of the types and workflow of lab testing currently in use. She gave us an easy to grasp explanation of methods and appropriate use for populations in testing. This was the best general session in my opinion.”

“This was a great and interesting presentation. Dr. Sweet is an obvious expert who understands how to relay the most relevant information with respect to the current culture, technology, and healthcare.”

Comments about Donna Sweet, MD, MACP

---

**NOTE:**

In response to the AIDS crisis, the Kansas State Congress enacted the Ryan White CARE (Comprehensive AIDS Resources Emergency) Act in August 1990 to improve the availability of care for low-income, uninsured, and underinsured individuals and families affected by HIV and AIDS. Click here for more information: [http://www.kdheks.gov/hiv/ryan_white_care.html](http://www.kdheks.gov/hiv/ryan_white_care.html)
Join us in Baltimore to learn more about Proficiency Testing.

Proficiency Testing Sessions

These sessions address various aspects of Proficiency Testing.

**A02 – Intro to Proficiency Testing**
*Presented by: Verlin Janzen, MD, FAAFP & John T. Daly, MD (LD Track)*

In this session, Dr. Janzen and Dr. Daly will focus on the basics of Proficiency Testing (PT). Physicians will learn how to select a PT provider, manage the PT process, and perform the laboratory director responsibilities relating to PT.

This session is designed for physician laboratory directors and for individuals without laboratory training.

**A04 – Getting the Most Out of Your Proficiency Testing**
*Presented by: Rick Gates, MLT(ASCP) & Leon Headley, MLS, CT(ASCP)*

Presented by veteran COLA employees deeply knowledgeable in the Proficiency Testing (PT) process, this session provides insight into how to review and evaluate your PT results so that you may identify problems and resolve PT failures when they occur. You will learn how to interpret your scores, recognize problems, and implement effective corrective actions to resolve PT problems.

Using PT to demonstrate quality and help to ensure accurate patient testing will also be discussed. Additionally, the session will relate PT performance review to COLA criteria and provide helpful suggestions for laboratories to achieve and maintain compliance with COLA and CLIA.

**Related Sessions**

Even though these sessions do not focus solely on PT specifically, they provide important related information that will prove useful in your laboratory.

**General Session – CLIA Hot Topics: Personnel Competency and IQCP**
*Presented by: Judy Yost, MA, MT(ASCP)*

This session will provide an update on

- Current CMS activities regarding annual personnel competency assessment, with guidance and tips to improve its efficiency and effectiveness in your laboratory while remaining in compliance with CLIA.
- The status of the recently published proposed Patient Access rule and the timing of plans to publish a final rule.
- The status of the planned changes to the PT regulations for laboratories and PT programs (a joint CDC and CMS effort).
- CMS’s new and exciting proposal for the new QC policy “IQCP,” the “Right QC,” and its guidance document (based on key CLSI EP-23 consensus document concepts). It will include CMS’s plans for its implementation, transition from EQC, educational period, and the potential impact on nonwaived CMS certified and accredited laboratories.

Case study examples will be used to illustrate
- how to identify problems;
- how to determine the root cause;
- how to formulate a solution, and
- how to follow up to see if the solution worked.

This session is designed for physician laboratory directors and for individuals without laboratory training.
General Session – Current Concerns & Potential Improvements  
Presented by: John T. Daly, MD

This session will explore two current areas of concern in laboratory medicine: waived testing and utilization of the technical consultant.

- Waived testing does not mean waived oversight! Waived testing is growing, but many waived labs have quality problems. There are many important considerations for good laboratory practices in pre-analytic, analytic, and post-analytic activities. The most common issues will be discussed during this session.

- The technical consultant (TC) position is one that is undervalued – until you hire a good one. Then you’ll say, “What did I ever do without this person?” During this session, Dr. Daly will compare the Lab director responsibilities with those of the TC, highlighting the areas where the TC can be invaluable in establishing good laboratory practices. He will also show when the physician lab director should NOT also hold the position of TC.

E44 – COLA Users Group: Accreditation Update  
Presented by: Irwin Rothenberg, MBA, MS, MT(ASCP) & Rachael Kelly

All CLIA accreditation programs begin with the core requirement to be in compliance with the Federal regulations. COLA’s approach emphasizes ready access to educational resources provided directly to laboratory staff and management, as the primary tool to achieve both regulatory compliance and a high quality laboratory operation responsive to its customer base.

At this Users Group session, participants will have the opportunity to review the COLA Accreditation process, consider COLA’s utilization of customer feedback as drivers to technological changes, and be introduced to COLA’s new Continuous Quality Program (CQP).

B12 – Personnel & Procedures for CLIA Compliance  
Presented by: Ann Bachman, CLC(AMT), MT(ASCP)

This session is a basic overview of some of the important aspects of the CLIA requirements. This session is designed to show the physician lab director how to meet the personnel requirements of a moderate complexity lab, and how to implement policies and procedures related to CLIA compliance.

Development of a lab procedure manual will be discussed. Participants will learn about the education and experience requirements necessary for personnel to hold the required CLIA-defined positions in the lab, and will review example policies and procedures that relate to physician office laboratory (POL) operations.

There will be an emphasis on clarification of terms and concepts associated with achieving CLIA compliance in a typical moderate complexity POL.

Lab Director Session – Preparing for Inspection  
Presented by: Ann Bachman, CLC(AMT), MT (ASCP)

To help alleviate some of the stress associated with laboratory surveys, this session will help you understand what the surveyors evaluate and what you need to do to prepare for their arrival. Handouts will include an Inspection Preparation Checklist.

General Session – Lab Director Responsibilities: Regulatory  
Presented by: Verlin Janzen, MD, FAAFP

Congratulations! You’re the Lab Director!

If you are a new laboratory director or want to learn more about the responsibilities and duties of directing a laboratory, this session will provide insight into the position. In this session, Dr. Janzen covers the basics of laboratory regulation, personnel issues, and general administrative duties relating to the laboratory director functions.
The Laboratory Conference that’s growing strong for you.

The must attend Laboratory Conference. Education, Exhibits, and You.

To learn more, please contact COLA at 1-800-981-9883 or visit us at www.cola.org